Studies have shown that active fund managers routinely underperform the S&P500 index*​

Liminatus Pharma, Inc. (NASDAQ: LIMN)

LIMN Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
NOT AVAILABLE
Analyst Forecast (1yr):
NOT AVAILABLE

LIMN Stock Analysis

LIMN PE Ratio:

LIMN PEG Ratio: Not Available

LIMN Forward EPS Growth (12 month): 0.00%

LIMN PS Ratio:

LIMN PSG Ratio: Not Available

LIMN Forward Revenue Growth (12 month): 0.00%

LIMN Articles

No data was found